FebriDx® Rapid Respiratory Test is a rapid point-of-care test that differentiates bacterial infections from non-bacterial pathogens. In 10 minutes, this portable test allows medical providers to initiate the correct treatment and avoid the overuse of antibiotics.

Features and Benefits:

Allows medical providers to identify or rule out bacterial infections
Delivers results within 10 minutes
No equipment necessary
Reduces the need to write antibiotic prescriptions
99% Negative predictive value
CLIA Moderate Waived Test

A quick and practical point-of-care diagnostic test, the Healgen® COVID-19/Flu A&B Ag Combo Rapid Test Cassette (Dual Windows) can identify and distinguish COVID-19, Influenza A, and Influenza B from a single nose swab sample.

The test uses sophisticated lateral flow immunochromatographic technology and yields clear results in around 15 minutes, assisting medical practitioners in making prompt clinical decisions. Because the COVID-19 and Flu A/B detection areas are clearly separated, the dual-window design enhances result interpretation. The test facilitates quick screening during respiratory illness seasons when COVID-19 and flu symptoms frequently coexist, making it ideal for people who are experiencing symptoms.

The Healgen Combo Test is an effective option for clinics, healthcare facilities, and point-of-care testing settings because of its straightforward sample collection, dependable performance, and capacity to identify three common respiratory viruses simultaneously. Through rapid and precise respiratory virus testing, it facilitates diagnosis, enhances patient care, and supports infection control initiatives.

WELLlife™ SARS-CoV-2/Flu A+B Rapid Antigen Test is a POC rapid antigen test that detects SARS-CoV-2, influenza A, and influenza B in 10 minutes. This point-of-care immunoassay offers a broader detection window within five days of symptom onset.

The controls kit provides external positive and negative controls designed to assess the performance and reliability of the FebriDx® test in professional settings. Easy to store, simple to run, and aligned with CLIA and manufacturer recommendations, these controls help ensure your results remain accurate, reproducible, and compliant—test after test.

Features and Benefits:
Delivers results after 10 minutes
No equipment necessary
CLIA Waived Test

WELLlife™ SARS-CoV-2/Flu A+B Rapid Antigen Test is a POC rapid antigen test that detects SARS-CoV-2, influenza A, and influenza B in 10 minutes. This point-of-care immunoassay offers a broader detection window within five days of symptom onset.

Features and Benefits:

Delivers results in 10 minutes
No equipment necessary
Covid-19: PPA 87.5%; NPA 99.7%
Flu A: PPA 85.9%; NPA 99.7%
Flu B: PPA 86.8%; NPA 99.7%
Nasal or nasopharyngeal swab samples
CLIA Waived Test

SAFE life™ 12-Panel C- Cup Multi-Drug Urine Test Cup was designed with your needs in mind. It is a lateral flow chromatographic immunoassay Point-of-Care Test for the simultaneous detection of multiple drugs and drug metabolites in human urine. Cups feature leak-resistant lids and a well at the bottom to allow for testing of a smaller sample volume.
Tests for Amphetamine (AMP), Barbiturates (BAR), Buprenorphine (BUP), Benzodiazepines (BZO), Cocaine (COC), Methylenedioxymethamphetamine (MDMA), Methadone (MTD), Opiate (OPI), Oxycodone (OXY), Phencyclidine (PCP), Tricyclic Antidepressants (TCA), Cannabinoids (THC).

DrySee®’s 2×2 +Pad Dressing is ideal for smaller wounds, cuts, and post-surgery incisions that need to be kept covered and dry. The perimeter liquid intrusion indicator on the waterproof bandage allows the wearer or caretaker to see if the bandage has been compromised from outside moisture. The inner pad liquid indicator will change color to alert that it has become saturated from wound fluid. Bandages can be worn for up to 4 days with no liquid indication.

Status™ Strep A Flip Rapid Point-of-Care Test is a immuno-chromatographic assay for detection of group A streptococcal antigen directly from a throat swab sample.

Features and Benefits:
Innovative Flip Test Design
Patented single-use reagent capsule
Sensitivity 96.0%; Specificity 99.0%
Delivers results within 5 minutes
No counting drops - less steps for greater accuracy
CLIA Waived Test

The Nano-Check™ RSV Test is a rapid immunochromatographic assay for the qualitative detection of respiratory syncytial virus (RSV) nucleoprotein antigen in anterior nasal swab specimens from patients with signs and symptoms of respiratory infections.
This test is intended for in vitro diagnostic use to aid in the diagnosis of RSV infections in infants and pediatric patients aged 6 months to 6 years old, and adults over 60 years of age.

Healgen™ Rapid Check RSV w/ PBS is a point-of-care chromatographic immunoassay for the qualitative detection of Respiratory Syncytial Virus (RSV) antigen. It is intended as a screening test and as an aid in the diagnosis of RSV respiratory infections.

CorDx Tyfast SARS-CoV-2/Flu A+B Rapid Antigen Point-of-Care Test is a lateral flow immunoassay intended for in vitro rapid, simultaneous qualitative detection and differentiation of nucleocapsid antigen from SARS-CoV-2, influenza A and influenza B directly from anterior nasal swab specimens obtained from patients who are suspected of COVID-19 by their healthcare provider, within the first five days of onset of symptoms.

Features and Benefits:
SARS-CoV-2/Flu A+B Rapid POC Combo Antigen Test
Simultaneous testing for acute respiratory infections caused by COVID-19, Flu A, Flu B
Lateral flow immunoassay
Covid-19: Sensitivity 89.6%; Specificity 99.8%
Flu A: Sensitivity 85%; Specificity 99.2%
Flu B: Sensitivity 87.5%; Specificity 99.8%
Nasal swab samples
Delivers results within 10 minutes
No equipment necessary
CLIA Waived Test

The GenBody COVID-19 Ag point-of-care test is a lateral flow chromatographic immunoassay intended for the qualitative detection of nucleocapsid protein antigen from the SARS-CoV-2 virus.

Features & Benefits

FDA EUA Authorized rapid antigen test
Anterior nasal swab specimen collection for comfort
Identifies acute infection with a 92.31% sensitivity and 99.04% specificity
Selected by NIH for the Rapid Acceleration of Diagnostics, for US production of the GenBody COVID-19 Ag test
Large manufacturing capacity and immediately available for distribution
For use in the Point-of-Care setting